Viltepso

Active Ingredient(s): Viltolarsen
FDA Approved: * August 12, 2020
Pharm Company: * NIPPON SHINYAKU
Category: Genetic Disorders

Viltolarsen, sold under the brand name Viltepso, is a medication used for the treatment of Duchenne muscular dystrophy (DMD).[2][3][1] Viltolarsen is a Morpholino antisense oligonucleotide.[2][1] The most common side effects include upper respiratory tract infection, injection site reaction, cough, and pyrexia (fever).[2][3][1] Viltolarsen was approved for medical us... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.